Chemoresistance represents a major problem in the treatment of many malignancies. Overcoming this obstacle will require improved understanding of the mechanisms responsible for this phenomenon. The progenitor cell marker NG2/melanoma proteoglycan (MPG) is aberrantly expressed by various tumors, but its role in cell death signaling and its potential as a therapeutic target are largely unexplored. We have assessed cytotoxic druginduced cell death in glioblastoma spheroids from 15 patients, as well as in five cancer cell lines that differ with respect to NG2/MPG expression. The tumors were treated with doxorubicin, etoposide, carboplatin, temodal, cisplatin and tumor necrosis factor (TNF)a. High NG2/ MPG expression correlated with multidrug resistance mediated by increased activation of a3b1 integrin/PI3K signaling and their downstream targets, promoting cell survival. NG2/MPG knockdown with shRNAs incorporated into lentiviral vectors attenuated b1 integrin signaling revealing potent antitumor effects and further sensitized neoplastic cells to cytotoxic treatment in vitro and in vivo. Thus, as a novel regulator of the antiapoptotic response, NG2/MPG may represent an effective therapeutic target in several cancer subtypes.
Introduction
Malignant brain tumors belong to the subgroup of cancers with the poorest prognosis, and the introduction of new chemotherapy regimens has only marginally improved survival. Attempts to improve survival must include strategies that identify and target molecules that confer chemoresistance. NG2 is a transmembrane chondroitin sulfate proteoglycan that is expressed by progenitor cells in several types of tissues (Stallcup, 2002) , including oligodendrocyte progenitors in the central nervous system (Nishiyama et al., 1996a; Belachew et al., 2003) . NG2 is the rat homolog of the human melanoma proteoglycan (MPG), also known as the high molecular weight melanoma-associated antigen (Pluschke et al., 1996; Campoli et al., 2004) . NG2/MPG is overexpressed by several tumor types that fail to respond to conventional chemotherapy, including glioblastomas (GBMs), most melanomas and some leukemias (Schrappe et al., 1991; Behm et al., 1996; Smith et al., 1996; Mauvieux et al., 1999; Shoshan et al., 1999; Chekenya et al., 2002a; Li et al., 2003) .
NG2/MPG potentiates cell motility (Burg et al., 1997; Eisenmann et al., 1999; Fang et al., 1999; Stallcup and Dahlin-Huppe, 2001; Makagiansar et al., 2004 Makagiansar et al., , 2007 and modulates responses to growth factors (Grako and Stallcup, 1995; Nishiyama et al., 1996b; Goretzki et al., 1999; Grako et al., 1999) , processes that are critical for the proliferation and migration of both immature progenitor and tumor cells. NG2/MPG expression increases melanoma growth and metastasis (Burg et al., 1998) , and enhances glioma growth and angiogenesis (Chekenya et al., 2002b) . The expression of NG2/MPG in childhood acute myeloid leukemic blasts has also been shown to correlate with poor clinical outcome Hilden et al., 1997) . The role of NG2/MPG in regulating cell death signaling is largely unexplored. We show here that by activating integrins and downstream PI3K/Akt signaling, NG2/MPG promotes tumor resistance to cytotoxic agents.
Results

NG2/MPG-expressing glioma cells are resistant to drug-induced apoptosis
Since tumor necrosis factor (TNFa) is a potent and wellcharacterized inducer of cell death, we compared its ability to induce apoptosis in NG2/MPG-negative U251 glioma cells (U251-wt) and U251 cells transfected with NG2/MPG (U251-NG2/MPG). Morphological analyses revealed more frequent nuclear condensation and DNA fragmentation in the U251-wt cells, indicating that they were significantly more sensitive to TNFa than the U251-NG2/MPG cells (Figures 1a and b ; Po0.024). Since TNFa also stimulates protein synthesis-dependent cell survival (Beg and Baltimore, 1996) , we investigated whether protein synthesis inhibition with cycloheximide increased sensitivity to TNFa. TNFa increased apoptosis in both U251-wt and U251-NG2/MPG cells ( Figures  1a and b) ; however, the extent of cell death in cycloheximide-treated U251-NG2/MPG cells remained less than in U251-wt cells. While these data support the existence of NG2/MPG-mediated survival signals that are protein synthesis independent, they do not rule out a component that is protein synthesis dependent. The requirement for caspases in TNFa-induced apoptosis was confirmed by the dramatic cell death inhibition for both U251-NG2/MPG and U251-wt (Figures 1a and b ) cells in the presence of zVAD. We also tested the effects of other drugs known to induce cell death (Figure 1c ). U251-NG2/MPG cells were less sensitive than U251-wt cells to etoposide and vincristine. In the latter case, the difference was small but still statistically significant. Our assessment of apoptosis was confirmed by flow cytometric analyses of DNA content during cell cycle progression (Figure 1d ). TNFa-induced apoptosis in U251-wt cells resulted in a large increase in the sub-G1 population, whereas this population was markedly smaller in the U251-NG2/MPG cells (Figure 1d ).
To assess the functional significance of NG2/MPG, we used rat sequence-specific siRNA2 to reduce the proteoglycan's expression in the U251-NG2 cells that overexpressed the rat ortholog (Figures 2a and b) , and human-specific siRNA3 in U87 cells that endogenously expressed the human homolog (Figures 2a and c) . These siRNAs reduced NG2/MPG protein levels in a dose-dependent manner and at low concentrations (10-25 nM) (Figures 2d and f) . The effect of siRNA treatment on NG2 mRNA levels was confirmed by attenuation of transcripts by approximately 75% in siRNA2-treated U251-NG2 cells (Figure 2e ). In contrast, a mutant siRNA2 with four consecutive mismatched nucleotides did not perturb NG2 mRNA levels, demonstrating that the NG2 siRNA knockdown was both sequence and target specific.
Next, we investigated the effect of NG2/MPG knockdown on TNFa-induced apoptosis. As shown in Figure 3a , the sensitivity of U251-NG2/MPG cells to TNFa treatment was significantly increased when NG2/ MPG expression was reduced by treatment with siRNA2 (analysis of variance (ANOVA) F 11.65 , df ¼ 2, P ¼ 0.0015). In contrast, U251-NG2/MPG cells transfected with control siRNA2 maintained their resistance to apoptosis. Intriguingly, siRNA knockdown sensitized U251-NG2/MPG cells to apoptosis beyond the levels seen in U251-wt cells, indicating that the proteoglyanpositive cells may be highly dependent on NG2/ MPG-mediated survival signals. NG2/MPG-dependent apoptosis resistance was also seen with U87 and A172 cells that endogenously express the proteoglycan (Figure 3b ). These cells are highly resistant to TNFainduced apoptosis, as are U87 and A172 cells transfected with control shRNA. In contrast, their sensitivity to TNFa was significantly increased by transfection with the shRNA3 species that effectively knocks down human NG2/MPG expression (Figure 3b ; immunoblots). U87wt cells and cells transfected with control shRNA were also resistant to clinically relevant chemotherapy drugs, but became sensitized upon shRNA-mediated NG2/MPG knockdown ( Figure 3c ). Flow cytometric analyses of DNA content during cell cycle progression also reflected the etoposide-induced increase in apoptosis in U87 cells treated with NG2/ MPG shRNAs, as visualized by the increased sub-G1 fraction in the DNA histograms. In addition, etoposide induced greater G2/M phase arrest in the NG2/MPG shRNA knockdown cells (Figure 3e) .
Similar results were also obtained with A375 melanoma cells that endogenously express human NG2/ MPG (Figure 3d ; immunoblot). Both Wt and control shRNA-transfected A375 cells were resistant to TNFa, doxorubicin and cisplatin, drugs commonly used for treatment of melanomas (Figure 3d ). However, shRNA3-transfected cells were significantly sensitized to these cytostatic agents (ANOVA F 12.01 , df¼ 8, Po0.0001). These findings establish NG2/MPGmediated chemoresistance as a general phenomenon associated with several tumor types.
The NG2/MPG proteoglycan interacts with the a3b1 integrin to mediate apoptosis resistance Integrin signaling plays a key role in regulating cell death and survival (Frisch and Ruoslahti, 1997; Wewer et al., 1997; Kumar, 1998; Damiano et al., 1999; Downward, 2004) . Since NG2/MPG has been shown to interact with b1 integrins (Burg et al., 1998; Eisenmann et al., 1999; Fukushi et al., 2004; Yang et al., 2004) , we investigated whether b1 integrin signaling could be involved in NG2/MPG-mediated resistance to cell death. U251-wt and U251-NG2/MPG cells were immunostained with the HUTS-21 mAb that recognizes an activation-dependent epitope in the human b1 integrin subunit (Luque et al., 1996) . While activated b1 integrin was barely detectable on U251-wt cells (Figure 4a (a) Hoechst-stained nuclei from U251-wt (top panels) and U251-NG2/MPG (bottom panels) cells exposed to 50 ng/ml TNFa with or without 1 mg/ml cycloheximide (CHX) for 3 or 6 h, magnification Â 200; scale bar ¼ 60 mm. (b) % apoptosis induced by TNFa with or without CHX at 3 h in U251-NG2/MPG cells or the U251-wt cells, assayed by nuclear fragmentation and DNA condensation as shown in (a). The data represent the mean ± s.e.m. from three independent experiments. (c) % cell death in U251-NG2/MPG and U251-wt glioma cells treated with 0.5 and 10 mM etoposide, or vincristine for 72 h and assayed by MTT. Data represent the mean±s.e.m. of three independent experiments. (d) Effect of TNFa (50 ng/ml) treatment for 6 h on apoptosis of U251-wt and U251-NG2/MPG cells, as determined by flow cytometric DNA analysis after staining with propidium iodide. In addition to illustrating the cell cycle distribution from G1 to G2-M, the DNA profiles quantify the appearance of apoptotic cells having less than G1 DNA content (sub-G1, blue). The histograms are representative of three independent experiments. Apoptosis resistance in NG2/MPG-expressing tumors M Chekenya et al antibody had a small, nonsignificant effect in U251-wt cells, perhaps due to blocking low levels of NG2/MPGindependent integrin b1 activation. Next, we asked whether activation of b1 integrin via an NG2/MPGindependent mechanism could rescue U251-wt cells from TNFa-induced apoptosis. Treating U251-wt cells with the b1-activating antibody TS2/16 (Hemler et al., 1984; Arroyo et al., 1992) , significantly protected the U251-wt cells from apoptosis (Po0.001; Figure 4c , left panel). Similarly, while U87wt cells and U87 cells transfected with control shRNA expressed equal levels of activated b1 integrin subunit, NG2/MPG knockdown with NG2 shRNA cells attenuated levels of activated b1 (Figure 4d ), further demonstrating the connection between NG2/MPG and integrin activation. Equivalent results were also obtained for A375 melanoma cells (data not shown). a3 integrin subunit levels were also comparable in U251-wt and U251-NG2/MPG (Figure 4e ), while a2, a4 and a6 subunits were barely detectable (data not shown). Thus, the a3b1 heterodimer is the predominant integrin in the U251 cells, but only displays the activated conformation in NG2/MPG-expressing cells. To provide evidence for a physical interaction between NG2/MPG and a3b1, we performed co-immunoprecipitation studies. The a3 subunit was detected in NG2/MPG immunoprecipitates prepared from both U251-NG2/MPG ( Figure 4f ) and U87 cells ( Figure 4h ) with two independent NG2/MPG antibodies but not with control immunoglobulins, demonstrating the specificity of the assays. The same two NG2/MPG antibodies did not immunoprecipitate a3 from the U251-wt cells (Figure 4g ), demonstrating the requirement for NG2/MPG in the co-immunoprecipitation. We were unable to demonstrate co-immunoprecipitation of NG2/MPG using antibodies against a3 integrin. Isotype-specific negative controls and a monoclonal a3 integrin blocking antibody had no effect on NG2/MPGmediated apoptosis resistance (data not shown). Taken together, these findings indicate the existence of an interaction between NG2/MPG and a3b1 integrin that promotes antiapoptotic signaling via activated b1 integrin.
NG2/MPG-a3b1-mediated resistance to TNFa-induced apoptosis requires PI3K/Akt signaling Since PI3K is a well-known promoter of cell survival acting downstream of b1 integrin, we studied the effect of the irreversible PI3K inhibitor wortmannin on TNFa-induced apoptosis in the U251-NG2/ MPG and U251-wt glioma cells (Figure 3a) . Wortmannin dramatically reduced the cytoprotective effect of NG2/MPG in U251-NG2/MPG cells treated with control siRNA as well as untreated cells (ANOVA F 45.27 , df¼ 1, Po0.002). In contrast, the effect was much smaller in U251-wt or U251-NG2/MPG siRNA knockdown cells already exhibiting high levels of cell death. These results indicate that NG2/MPG expression protects cells from TNFa-induced cell death via a mechanism involving the PI3K/Akt survival pathway.
To generate support for this hypothesis, we compared levels of the PI3K product, PtdIns (3,4,5) P3 in U251-wt and U251-NG2/MPG cells. Measurement of [ 32 P]-radiolabeled PtdIns (3,4,5) P3 under basal conditions revealed increased synthesis of this phospholipid in the apoptosis-resistant U251-NG2/MPG cells (t 4.262 , df ¼ 4; P ¼ 0.01) (Figure 5a ), but TNFa increased PIP3 levels in both cell types (t 1.024 , df ¼ 2; P ¼ 0.413) (Figure 5a ). Quantitative assessment of Akt (S473) phosphorylation revealed a twofold greater baseline phosphorylation in U251-NG2/MPG cells compared to U251-wt cells (Supplementary Figure 1) adding further support for activation of PI3K/Akt as downstream targets of NG2/ MPG-dependent a3b1 integrin signaling. These data suggest that the NG2/MPG-positive cells may be primed for drug resistance.
Similar to U251-NG2/MPG cells, constitutively high levels of S473 phospho-Akt were also demonstrated in U87 (Figure 5b ), A172 ( Figure 5c ) and A375 cells (Figure 5d ) that endogenously express NG2/MPG. Transfection of these cells with NG2/MPG siRNA3, but not control siRNA, attenuated levels of S473 phospho-Akt (Figures 5b-d) , substantiating the link between NG2/MPG expression and increased PI3K/Akt signaling.
NG2/MPG promotes resistance to TNFa and enhances tumor growth in vivo To determine whether NG2/MPG-induced apoptosis resistance affects tumor growth, U87 cells were infected with lentiviruses expressing green fluorescent protein (GFP) and either control shRNAs (U87LVcontrol shRNA), or NG2/MPG shRNAs (U87LVNG2/MPG shRNA). At 96 h after a single exposure to the lentivirusencoding NG2/MPG shRNAs, 65% of the cells expressed GFP compared to uninfected cells (Figures 6a and b) . Western blot analyses confirmed that while both the U87 parental and U87LVcontrol shRNA cells contained high levels of NG2/MPG protein, successful downregulation of the NG2/MPG protein was achieved in the U87LVNG2/ MPG shRNA cells (Figure 6c ). The knockdown of NG2/ MPG was associated with significant tumor growth inhibition in vivo (ANOVA, F 20.92 df ¼ 3, P ¼ 0.0004; Figures 6d and e).
To determine whether knocking down NG2/MPG affects tumor sensitivity to TNFa in vivo, the U87LVcontrol shRNA and U87LVNG2/MPG shRNA tumor-bearing mice were treated with TNFa. This treatment had little effect on the growth of U87LVcon-trol shRNA tumors (Figures 6d and e) . However, the growth of U87LVNG2/MPG shRNA tumors was further retarded, indicating that they had been sensitized to TNFa treatment. Immunoblot analyses of tumor lysates revealed that while U87LVcontrol shRNA tumors had detectable levels of NG2/MPG (Figure 6f , right panels), successful knockdown of NG2/MPG (Figure 6f, left panels) . Moreover, while levels of b-actin and total Akt remained largely unchanged across the groups (Figure 6f) , levels of phosphorylated Akt were attenuated in the U87LVNG2/MPG shRNA tumors (Figure 6f ). Using TdT-mediated dUTP nick end labeling (TUNEL) staining, we were able to document increased tumor cell death after NG2/MPG Figure 4 Apoptosis resistance in NG2/MPG cells is mediated by b1 integrin signaling. (a) Activated b1 integrin (HUTS-21, green, top panels) or total b1 integrin TS2/16, green, bottom panels) in U251-wt (left) and U251-NG2/MPG (right), magnification Â 400, scale bar 60 mm. (b) Activated b1 (HUTS-21, green, top left); total b1 (TS2/16, green, bottom left) subunits in U251-wt and U251-NG2/ MPG cells determined by flow cytometry. % values reflect the total fluorescence intensity relative to an arbitrary window setting. Control profiles were obtained by using secondary antibody alone. (c) Left panel: % apoptosis in U251-wt cells pre-incubated with b1-activating antibody TS2/16 (10 mg/ml) for 30 min or with CD29-blocking antibody Ha2/5 for 2 h prior to 6 h treatment with 50 ng/ ml TNFa. Right panel: % apoptosis in U251-NG2/MPG cells pre-incubated with b1 function-blocking antibodies (CD29 Ha2/5 or AIIB2) for 2 h prior to treatment with 50 ng/ml TNFa. Apoptosis was assayed by nuclear fragmentation and DNA condensation. Each bar represents the mean ± s.e.m. of three independent experiments. (d) Activated b1 integrin levels in U87wt, U87 ctrl siRNA and U87 NG2/MPG siRNA cells determined by HUTS-21 flow cytometry. % values reflect the total fluorescence intensity relative to an arbitrary window setting. Control profiles were obtained by using secondary antibody alone. (e) a3 integrin subunits in U251-wt and U251-NG2/MPG cells were determined by flow cytometry. % values reflect the total fluorescence intensity relative to an arbitrary window setting. Control profiles were obtained by using secondary antibody alone. 
NG2/MPG expression is associated with chemoresistance in human GBM
To validate the physiological relevance of our observations in human tissues, GBM biopsy spheroids derived from tumors with varying NG2/MPG levels ( Figure 7a and Table 1 ) were examined for chemosensitivity to doxorubicin, etoposide and carboplatin (Figure 7b ). Spheroids from GBMs with high NG2/MPG expression, as determined by both immunohistochemistry and qPCR, were resistant to doxorubicin, etoposide and carboplatin ( Figure 7b ). In contrast, the GBM samples with low NG2/MPG exhibited greater sensitivity to these agents. These findings strongly link NG2/MPG expression to chemoresistance in glioma samples.
Discussion
The present study demonstrates a novel role for NG2/ MPG in mediating protection from apoptosis induced by TNFa and by other cytotoxic drugs with different modes of action. This effect is seen in a panel of cancer cell lines, as well as in biopsy material from brain tumor patients. Furthermore, knockdown of NG2/MPG sensitized malignant cells to chemotherapy and suppressed the growth rates of gliomas in vivo.
We provide evidence via co-immunoprecipitation and immunoblotting studies that the mechanism responsible for these effects involves complexing of NG2/MPG with a3b1 integrin on the cell surface, with subsequent activation of the PI3K/Akt signaling pathway. While levels of total b1 and a3 integrin subunits were unchanged in both U251-wt and U251-NG2/MPG cells, increased levels of activated b1 integrin were observed in U251-NG2/MPG compared to U251-wt cells. Furthermore, inhibition of integrin-mediated signaling using b1 function-blocking antibodies attenuated apoptosis resistance in the NG2/MPG-expressing cells, identifying a3b1 integrin as an important mediator of NG2/MPGdependent survival signaling in cancer cells. Our results indicate that NG2/MPG-mediated a3b1 activation results in survival signals transduced via stimulation of PI3K/Akt signaling, a pathway widely recognized as a mediator of cell survival signaling (Cantrell, 2001; Vivanco and Sawyers, 2002) . It is likely that this same PI3K/Akt signaling cascade mediates the integrindependent increase in cell motility that occurs in response to NG2/MPG expression Makagiansar et al., 2007) . Integrin-dependent effects of NG2 on apoptosis may vary according to the cell type and the nature of the environmental stimuli received by the cell. For example, under inflammatory conditions, NG2 can promote anoikis in fibroblasts by opposing fibronectin-stimulated a4b1 integrin signaling via a PKCa-dependent mechanism (Joo et al., 2008) .
Our initial experiments utilized U251 cells overexpressing NG2/MPG to assess the proteoglycan's effect Apoptosis resistance in NG2/MPG-expressing tumors M Chekenya et al on chemosensitivity. From a therapeutic point of view, it was equally informative to study the effects of downregulating NG2/MPG in tumor cell lines that constitutively express the proteoglycan. Taken together, these studies demonstrated that heterologous expression of NG2/MPG confers resistance to apoptosis in cells that are normally NG2/MPG negative, while downregulation of endogenous NG2/MPG expression leads to increased sensitivity to TNFa-induced apoptosis. In addition, the relevance of these findings was validated in human GBM biopsy spheroids where low NG2/MPG expression correlated with chemosensitivity to doxorubicin, etoposide and carboplatin. In contrast, tumors with high levels of NG2/MPG were more resistant to, and in some cases were even stimulated to higher metabolic activity, by this cytotoxic treatment. This increased metabolic activity may be a result of energyconsuming processes such as drug efflux or active DNA repair processes. The chemotherapeutic drugs used in this study serve as proof of principle to demonstrate that NG2/MPG-expressing cells can be sensitized to various drugs after knockdown of proteoglycan expression.
We have confirmed that the U251-wt and U251-NG2/ MPG cell lines carry identical alterations in PTEN and p53 (Supplementary Figures 3 and 4, respectively) , while these genes were differentially altered in the endogenously expressing cells (Supplementary Table 1 ). This demonstrates that differences in apoptosis resistance between these lines are likely to be due to the effects of NG2/MPG rather than to different genetic backgrounds. The overexpression studies and the siRNA knockdown studies clearly demonstrate the cause-effect relationship between the presence of the proteoglycan and resistance to apoptosis.
The in vivo studies reveal two distinct effects of NG2/ MPG on tumor progression. First, the differential effects of TNFa on U87 tumors transfected with control or NG2/MPG shRNAs demonstrate the protective effect of NG2/MPG against TNFa-induced apoptosis. Further comparisons of these tumors revealed higher levels of phospho-Akt in the NG2/MPG-expressing tumors, indicative of increased PI3K/Akt signaling in support of the in vitro data. Second, stable downregulation of NG2/MPG in U87 (mediated by lentivirally delivered shRNAs) led to marked reduction of tumor growth rates even in the absence of TNFa. This effect may be due to NG2/MPG's role in functions that are unrelated to apoptosis. For example, NG2/MPG potentiates cell proliferation, possibly as a result of its participation in growth factor signaling (Goretzki et al., 1999; Grako et al., 1999) . NG2/MPG also stimulates angiogenesis, by sequestering angiostatin and neutralizing its inhibitory effects on angiogenesis (Goretzki et al., 2000; Chekenya et al., 2002b) .
In conclusion, we have applied a variety of experimental conditions to both in vitro and in vivo model systems, all of which establish NG2/MPG as a mediator of multidrug resistance in the tumors examined. The mechanisms responsible for these effects involve increased survival signals that counteract cell death. Future work will be directed at elucidating in more depth the genetic or epigenetic mechanisms involved in the NG2/MPG-induced chemoresistance. This involvement of NG2/MPG in multiple aspects of tumor biology makes the proteoglycan an attractive candidate for future therapies against cancer.
Materials and methods
Cell culture
These studies utilized the human GBM multiforme cell lines U251N (U251-Wt), U87 and A172 and the human A375 melanoma (American Type Culture Collection (ATCC), Rockville, Maryland, USA). U251 cells were transfected with the rat NG2/MPG cDNA (U251-NG2/MPG), as previously described (Chekenya et al., 2002b) . Cells were exposed to 50 ng/ml TNFa for 15 min with or without 30 min pretreatment with the PI3K inhibitor Wortmannin (Sigma, St Louis, MO, USA). The chemotherapy agents vincristine, etoposide, temodal, doxorubicin, cisplatin and carboplatin were also used. In some experiments, cells were pretreated for 20 min with the irreversible caspase inhibitor zVAD-FMK (BIOMOL, Plymouth Meeting, PA, USA). Cells were also pre-incubated with 10 mg/ml of TS2/16 b1-activating antibody (ATCC), or CD29 (/Ha2/5) b1 function-blocking antibody (BD Pharmingen, San Diego, CA, USA), or the b1 integrin functionblocking monoclonal antibody AIIB2 (a gift from M Bissell) at 37 1C for 2 h prior to treatment with TNFa. Prior to analysis of apoptosis, cells were fixed in 2% (v/v) glutaraldehyde containing 1 mg/ml Hoechst 33342 (Sigma).
Scoring of apoptosis
Apoptosis was determined by morphological changes in Hoechst-stained cell nuclei using light and UV microscopy as previously described (Sandal et al., 2002) . Apoptosis (sub-G1 population) was also assessed by flow cytometric analysis of DNA content in cells stained with propidium iodide using ModFit LT version 3.0 software. For fluorescence, goat antimouse quantum dots 565 (Invitrogen, Carlsbad, CA, USA) were used. Negative controls were secondary antibody only.
Sensitivity of human GBM biopsy spheroids to doxorubicin
To assess viability/metabolic activity in NG2/MPG-positive (n ¼ 8) and -negative (n ¼ 7) human glioma specimens, spheroids of equal sizes (250 mm) were treated with 3 mM doxorubicin (96 h), or 0.5 and 50 mM etoposide (120 h) or 0.5 and Figure 7 . NG2/ MPG levels were determined by real-time qPCR, except in cases marked ND (not determined) in which NG2/MPG levels were assessed semiquantitatively by IHC. High NG2/MPG expression was defined as being greater than that seen in normal brain (that is, greater than onefold change). Low expressors (top of the list) are separated from high expressors (bottom of the list) by a space. % viable cells were determined via MTS assays, as absorbance of non-treated cells-absorbance of treated cells)/absorbance of non-treated cells. Values greater than 100% therefore represent samples, which had increased metabolic activity in the presence of the drug. These results were pooled to yield the histograms in Figure 7b . Apoptosis resistance in NG2/MPG-expressing tumors M Chekenya et al 10 mM carboplatin (120 h) depending on the nearest IC 50 value for the NG2/MPG-negative tumors. The 3-(4-5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt assay was used as described by the manufacturer (Promega, Madison, WI, USA). Untreated spheroids were used as controls. The effects of drugs (% of control) were calculated as absorbance of non-treated cellsabsorbance of treated cells)/absorbance of non-treated cells (Miura et al., 2006) . The ethical board at Haukeland University Hospital, Bergen, Norway, approved the collection of tumor tissue. The patients gave their informed consent to specimen collection.
Real-time qPCR
The snap frozen GBM tissue was crushed in liquid nitrogen, total RNA was extracted and cDNA reverse transcribed using iScript (Bio-Rad Laboratories, Hercules, CA, USA), with iQ SYBR Green in the real-time qPCR using iCycler Thermal Cycler fitted with iCycler Optical Module (Bio-Rad Laboratories). Primers directed against 18S RNA were used as an internal control. Three adult normal brain cDNAs used as reference were either prepared from cerebral cortical tissue after radical resection and verified by a neuropathologist, or were purchased from Ambion (Austin, TX, USA).
siRNA synthesis siRNAs were transcribed in vitro using chemically synthesized DNA oligonucleotides and T7 RNA polymerase. The following siRNAs were designed: siRNA2 5 0 -GUAGAUCAAU ACCCUACACUU-3 0 (positions 970-989) in the rat NG2/ MPG cDNA. A non-functional mutant version of siRNA2 with four consecutive nucleotide mismatches was used as a control (5 0 -GUAGAUCAAUUGGGUACACUU-3 0 ). The expression of human NG2/MPG was targeted with siRNA3 (5 0 -GUGGACCAGUACCCUACGG-3 0 ), corresponding to Homo sapiens melanoma-associated chondroitin sulfate proteoglycan (cspg4).
Construction of the shRNA lentiviral vectors and lentiviral infection Lentiviral particles harboring pRNAt-U6.1 (SD 1257; Genscript, Scotch Plains, NJ, USA), encoding a U6 promoter driving shRNA expression were produced using the Virapower lentiviral packaging mix (Invitrogen) according to the manufacturer's descriptions. Briefly, packaging plasmids and transfer vectors were co-transfected into 293FT cells, and viral particles were harvested 48 h post-infection. Viral particles were concentrated by ultra-centrifugation and the infected cells were monitored for GFP expression using flow cytometry (FACS Calibur; BD, Erembodegem, Belgium). At 2 weeks post-infection, the cells were harvested and monitored for GFP fluorescence by flow cytometry. Table 1 .
Western blotting
Proteins from cells or tumor tissue were harvested in ice-cold lysis buffer (10 mM K2HPO4, 1 mM EDTA (pH 6.8) containing 10 mM Chaps, 50 mM NaF and 0.3 mM NaVO3, supplemented with Complete Protease Inhibitor (Roche Molecular Biochemicals, Basel, Switzerland) and 0.02 U of chondroitinase ABC (Sigma). Rabbit anti-total Akt and anti-phospho Akt (Ser 473) (diluted 1:1000) (Cell Signalling Technology, Beverly, MA, USA) and rabbit anti-NG2/MPG (553) antibody was used at 1:2000 dilution. For normalization, blots were stripped and re-probed with mouse anti-b-actin (diluted 1:5000, Abcam Limited, Cambridge, UK). Immunoprecipitations were performed as previously described . Immunocyto/histochemistry was performed using standard procedures as previously described (Chekenya et al., 2002b) .
Extraction and analysis of 3-phosphorylated glycerophosphoinositides U251-wt and U251-NG2/MPG glioma cells treated with 50 ng/ml TNFa for 15 min were propagated in the presence of [
32 P] Pi to produce [ 32 P]-labeled phospholipids. Extraction and thin-layer chromatography of polyphosphoinositides were performed as described previously (Tysnes et al., 1985) .
Animals
Twenty-four, 5-to 6-week old, severe combined immunodeficient (NOD-SCID) mice (C.B. -Igh-1b/lcrTac-Prkdc) purchased from Taconic Europe (Ry, Denmark) received 5 Â 10 6 U87MG tumor cells stably expressing LVNG2/MPG shRNAs and LVCtr shRNA lentiviruses into the hind leg. The animals were divided into four groups, U87MG LV-control siRNA (n ¼ 6), U87MG LVNG2/MPG siRNA (n ¼ 6), U87MG LV control siRNA þ TNFa (n ¼ 6) and U87MG LVNG2/MPG siRNA þ TNFa (n ¼ 6). At 48 h after tumor implantation, the two treatment groups were treated with intraperitoneal injections (IP) of 150 mg/kg rhTNFa, (Peprotech Ltd, London, UK), once a day for 7 days. The animals were anaesthetized with 1-2% isoflurane in a 70/30% N 2 /O 2 mix and all procedures were in accordance with protocols approved by The National Animal Research Authority (Oslo, Norway). Tumor growth was determined by measuring two perpendicular diameters. Tumor volumes (V) were calculated using the formula (V) ¼ (a Â b Â c)/2 that was derived for an ellipsoid (pd 3 /6) (Tan et al., 2004) , where a, b and c are the long axis, short axis and the depth, respectively.
Statistical analyses
Data were analysed using the Student's paired t-test (twotailed), and one-way (StatViewSE þ ) or two-way ANOVA (Graphpad Instat software Inc version 3.05, San Diego, CA, USA).
